LD 107: An Act To Require Health Insurance Coverage For Biomarker Testing
LD 107 status: Introduced — Died in Possession of the Senate when the Legislature adjourned Sine Die and was PLACED IN THE LEGISLATIVE FILES. (DEAD) (updated Apr 29, 2026).
What this bill does
Overall score
Bill summary
OfficialAn Act To Require Health Insurance Coverage For Biomarker Testing. Currently in House.
Key analysis
Impact analysis
Environment
Benefits
- No identified impact on environmental policy
Risks
- No identified impact on environmental policy
Economy
Benefits
- Potential reduction in long-term treatment costs through personalized medicine
Risks
- Potential for increased insurance premiums due to expanded mandate coverage
Society
Benefits
- Increases patient access to targeted, high-precision medical diagnostics
- Supports improved clinical outcomes through personalized treatment paths
Risks
- Implementation relies on provider availability of specialized testing
How trustworthy & consequential it is
Source
OpenStates
Confidence
lowlow
Analysis status
OpenStates summary
Mandated coverage typically exerts upward pressure on private insurance premiums
Analysis based solely on abstract; full bill text not reviewed
Where it stands
Introduced
CurrentDied in Possession of the Senate when the Legislature adjourned Sine Die and was PLACED IN THE LEGISLATIVE FILES. (DEAD)
Committee
UpcomingFloor
UpcomingGovernor
UpcomingEnacted
UpcomingHow it affects your district
Set your location
Add your district to see how this bill may affect your community and who to contact.
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.